vs
Side-by-side financial comparison of SMITH & WESSON BRANDS, INC. (SWBI) and Vericel Corp (VCEL). Click either name above to swap in a different company.
SMITH & WESSON BRANDS, INC. is the larger business by last-quarter revenue ($124.7M vs $92.9M, roughly 1.3× Vericel Corp). Vericel Corp runs the higher net margin — 25.0% vs 1.5%, a 23.5% gap on every dollar of revenue. On growth, Vericel Corp posted the faster year-over-year revenue change (23.3% vs -3.9%). SMITH & WESSON BRANDS, INC. produced more free cash flow last quarter ($16.3M vs $12.8M). Over the past eight quarters, Vericel Corp's revenue compounded faster (34.6% CAGR vs -4.8%).
Smith & Wesson Brands, Inc. (S&W) is an American firearm manufacturer headquartered in Maryville, Tennessee, United States.
Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan.
SWBI vs VCEL — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $124.7M | $92.9M |
| Net Profit | $1.9M | $23.2M |
| Gross Margin | 24.3% | 78.7% |
| Operating Margin | 3.3% | 24.1% |
| Net Margin | 1.5% | 25.0% |
| Revenue YoY | -3.9% | 23.3% |
| Net Profit YoY | -53.6% | 17.3% |
| EPS (diluted) | $0.04 | $0.46 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $124.7M | $92.9M | ||
| Q3 25 | $85.1M | $67.5M | ||
| Q2 25 | $140.8M | $63.2M | ||
| Q1 25 | $115.9M | $52.6M | ||
| Q4 24 | $129.7M | $75.4M | ||
| Q3 24 | $88.3M | $57.9M | ||
| Q2 24 | $159.1M | $52.7M | ||
| Q1 24 | $137.5M | $51.3M |
| Q4 25 | $1.9M | $23.2M | ||
| Q3 25 | $-3.4M | $5.1M | ||
| Q2 25 | $8.6M | $-553.0K | ||
| Q1 25 | $2.1M | $-11.2M | ||
| Q4 24 | $4.5M | $19.8M | ||
| Q3 24 | $-1.9M | $-901.0K | ||
| Q2 24 | $27.9M | $-4.7M | ||
| Q1 24 | $7.9M | $-3.9M |
| Q4 25 | 24.3% | 78.7% | ||
| Q3 25 | 25.9% | 73.5% | ||
| Q2 25 | 28.8% | 73.7% | ||
| Q1 25 | 24.1% | 69.0% | ||
| Q4 24 | 26.6% | 77.6% | ||
| Q3 24 | 27.4% | 71.9% | ||
| Q2 24 | 35.5% | 69.5% | ||
| Q1 24 | 28.7% | 68.9% |
| Q4 25 | 3.3% | 24.1% | ||
| Q3 25 | -3.5% | 5.1% | ||
| Q2 25 | 9.3% | -3.2% | ||
| Q1 25 | 4.1% | -24.3% | ||
| Q4 24 | 5.8% | 24.5% | ||
| Q3 24 | -1.7% | -4.3% | ||
| Q2 24 | 17.4% | -11.5% | ||
| Q1 24 | 8.2% | -10.7% |
| Q4 25 | 1.5% | 25.0% | ||
| Q3 25 | -4.0% | 7.5% | ||
| Q2 25 | 6.1% | -0.9% | ||
| Q1 25 | 1.8% | -21.4% | ||
| Q4 24 | 3.5% | 26.3% | ||
| Q3 24 | -2.1% | -1.6% | ||
| Q2 24 | 17.5% | -8.9% | ||
| Q1 24 | 5.7% | -7.5% |
| Q4 25 | $0.04 | $0.46 | ||
| Q3 25 | $-0.08 | $0.10 | ||
| Q2 25 | $0.19 | $-0.01 | ||
| Q1 25 | $0.05 | $-0.23 | ||
| Q4 24 | $0.10 | $0.40 | ||
| Q3 24 | $-0.04 | $-0.02 | ||
| Q2 24 | $0.60 | $-0.10 | ||
| Q1 24 | $0.17 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $22.4M | $137.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $363.2M | $354.6M |
| Total Assets | $548.6M | $488.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $22.4M | $137.5M | ||
| Q3 25 | $18.0M | $135.4M | ||
| Q2 25 | $25.2M | $116.9M | ||
| Q1 25 | $26.7M | $112.9M | ||
| Q4 24 | $39.1M | $116.2M | ||
| Q3 24 | $35.5M | $101.7M | ||
| Q2 24 | $60.8M | $102.5M | ||
| Q1 24 | $47.4M | $110.6M |
| Q4 25 | $363.2M | $354.6M | ||
| Q3 25 | $364.4M | $321.9M | ||
| Q2 25 | $372.5M | $306.8M | ||
| Q1 25 | $366.9M | $295.5M | ||
| Q4 24 | $371.5M | $292.0M | ||
| Q3 24 | $380.0M | $257.5M | ||
| Q2 24 | $399.9M | $243.0M | ||
| Q1 24 | $376.4M | $233.9M |
| Q4 25 | $548.6M | $488.0M | ||
| Q3 25 | $554.6M | $453.3M | ||
| Q2 25 | $559.6M | $435.6M | ||
| Q1 25 | $578.9M | $424.6M | ||
| Q4 24 | $587.4M | $432.7M | ||
| Q3 24 | $571.3M | $390.4M | ||
| Q2 24 | $577.4M | $376.8M | ||
| Q1 24 | $570.6M | $356.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $27.3M | $15.0M |
| Free Cash FlowOCF − Capex | $16.3M | $12.8M |
| FCF MarginFCF / Revenue | 13.1% | 13.8% |
| Capex IntensityCapex / Revenue | 8.8% | 2.4% |
| Cash ConversionOCF / Net Profit | 14.22× | 0.65× |
| TTM Free Cash FlowTrailing 4 quarters | $21.3M | $24.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $27.3M | $15.0M | ||
| Q3 25 | $-8.1M | $22.1M | ||
| Q2 25 | $40.8M | $8.2M | ||
| Q1 25 | $-9.8M | $6.6M | ||
| Q4 24 | $-7.4M | $22.2M | ||
| Q3 24 | $-30.8M | $10.2M | ||
| Q2 24 | $43.7M | $18.5M | ||
| Q1 24 | $25.2M | $7.2M |
| Q4 25 | $16.3M | $12.8M | ||
| Q3 25 | $-12.4M | $19.5M | ||
| Q2 25 | $33.5M | $81.0K | ||
| Q1 25 | $-16.1M | $-7.6M | ||
| Q4 24 | $-10.7M | $8.5M | ||
| Q3 24 | $-35.5M | $-9.2M | ||
| Q2 24 | $38.2M | $1.8M | ||
| Q1 24 | $7.0M | $-6.8M |
| Q4 25 | 13.1% | 13.8% | ||
| Q3 25 | -14.6% | 28.8% | ||
| Q2 25 | 23.8% | 0.1% | ||
| Q1 25 | -13.9% | -14.5% | ||
| Q4 24 | -8.3% | 11.2% | ||
| Q3 24 | -40.2% | -15.9% | ||
| Q2 24 | 24.0% | 3.4% | ||
| Q1 24 | 5.1% | -13.3% |
| Q4 25 | 8.8% | 2.4% | ||
| Q3 25 | 5.0% | 3.9% | ||
| Q2 25 | 5.2% | 12.9% | ||
| Q1 25 | 5.4% | 27.0% | ||
| Q4 24 | 2.5% | 18.3% | ||
| Q3 24 | 5.3% | 33.5% | ||
| Q2 24 | 3.5% | 31.8% | ||
| Q1 24 | 13.2% | 27.3% |
| Q4 25 | 14.22× | 0.65× | ||
| Q3 25 | — | 4.35× | ||
| Q2 25 | 4.73× | — | ||
| Q1 25 | -4.68× | — | ||
| Q4 24 | -1.63× | 1.12× | ||
| Q3 24 | — | — | ||
| Q2 24 | 1.57× | — | ||
| Q1 24 | 3.20× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SWBI
Segment breakdown not available.
VCEL
| MACI Implants And Kits | $84.1M | 90% |
| Other | $8.8M | 10% |
